Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.58 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26985749 | 0.83 | SIGMAR1 (0.70) | SIGMAR1TMEM97SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL26985700 | 0.82 | SIGMAR1 (0.73) | SIGMAR1TMEM97SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25047608 | 0.80 | SIGMAR1 (0.66) | SIGMAR1TMEM97SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6807356 | 0.79 | SIGMAR1 (0.63) | SIGMAR1TMEM97SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4726672 | 0.79 | TDP1 (0.46) | SLC6A3 | |
| SCHEMBL4520076 | 0.79 | SIGMAR1 (0.55) | SIGMAR1TMEM97SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7440692 | 0.78 | SIGMAR1 (0.62) | SIGMAR1SLC6A2SLC6A4SLC6A3TAAR1 | |
| SCHEMBL9180229 | 0.77 | CYP1A2 (0.61) | SLC6A2AOC3 | |
| Demelverine SCHEMBL1516521 | 0.77 | SIGMAR1 (0.76) | SIGMAR1SLC6A2SLC6A4SLC6A3TAAR1 | |
| SCHEMBL6968328 | 0.76 | SIGMAR1 (0.72) | SIGMAR1SLC6A2SLC6A4SLC6A3FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221653-A1 | 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| EP-1937656-A1 | 7-(2-AMINO-1-HYDROXY-ETHYL)-4-HYDROXYBENZOTHIAZOL-2(3H)-ONE-DERIVATIVES AS BETA 2 ADRENOCEPTOR AGONISTS | AstraZeneca AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007027134-A1 | 7-(2-AMINO-1-HYDROXY-ETHYL)-4-HYDROXYBENZOTHIAZOL-2(3H)-ONE-DERIVATIVES AS β2 ADRENOCEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221653-A1 | 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists | ADRB2, ADRB1, ADRA2C | SIGMAR1 174/4885TMEM97 273/4885SLC6A2 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.